Recently Featured

Padcev-Keytruda Combo Delivers More Positive Data in Bladder Cancer

March 3, 2026
Researchers have unveiled promising results for the Padcev-Keytruda combination, demonstrating its efficacy as a first-line treatment for a specific type of bladder cancer. This marks the second significant achievement for the duo, following last year’s favorable outcomes that highlighted their potential in oncology. The continued success of this combination therapy underscores a growing trend in…

Novartis finalizes $12 billion Avidity acquisition as Atrium Therapeutics emerges

March 2, 2026
Novartis has officially completed its $12 billion acquisition of Avidity Biosciences, a move that underscores its commitment to advancing RNA-based therapies for rare muscle diseases. This strategic acquisition coincides with the launch of Atrium Therapeutics, a spinout that will focus on Avidity’s early-stage programs targeting genetic cardiomyopathies, conditions that affect the heart muscle and can…

Merck to Wind Down Gardasil Production at N.C. Plant, Lay Off 150-Plus

March 2, 2026
Merck has announced the impending cessation of Gardasil and Gardasil 9 production at its Durham, North Carolina facility, resulting in the layoff of 147 employees. This decision stems from a notable decline in global demand for these vaccines, as detailed in a Worker Adjustment and Retraining Notification Act alert issued this week. The reduction in…

Investors Inject Millions into AI Solutions for Health Insurers

March 2, 2026
In the past month, payer AI startups such as Anterior, Daffodil Health, and Alaffia Health have collectively raised tens of millions in venture funding. This surge in investment underscores a growing trend where health insurers are increasingly adopting advanced AI technologies to enhance operational efficiency and patient care, striving to keep pace with hospitals and…

Ongoing Cases